Skip to content
IFAI

Isomorphic Labs

Company4 stories

  1. ResearchReach 31

    DeepMind's playbook to stop AI bioweapons and pandemics

    Google DeepMind and Isomorphic Labs just unveiled a joint bioresilience strategy to tackle biological threats and future outbreaks. Over the past year, they formed over 15 partnerships, deploying tools like AlphaFold, AlphaEvolve, and Isomorphic's drug design engine for pathogen surveillance and vaccine discovery. They are also adapting SynthID watermarking to screen AI-generated biological sequences. Why it matters: As frontier AI lowers the bar for biological modeling, tech giants are racing to build defenses before the risks outpace containment.

  2. IndustryReach 48

    Isomorphic Labs is in talks to raise over $2 billion

    Isomorphic Labs is in advanced talks to raise more than $2 billion in a new funding round led by Thrive Capital. The AI drug discovery startup, spun out of Alphabet's Google DeepMind, will also see Alphabet participate. The massive deal underscores that big-ticket investor appetite for AI pharmaceuticals remains sky-high.